WALTHAM, MA., August 20, 2018 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of…
Responses to the last of four outstanding action items submitted; Potential to start clinical study in the Third Quarter of 2018 WALTHAM, Mass., June 22, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today…
WALTHAM, Mass., Oct. 23, 2017 — EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing products using two proprietary platform technologies for treating diseases and disorders of the eye, has appointed two distinguished leaders in the ophthalmic space, Vance Thompson, MD and Paul Karpecki, OD, FAAO,…
On track to report topline data in 2Q18 and file NDA within 2018 WALTHAM, Mass., Dec. 18, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, reported that the Phase 3 pivotal trial of EGP-437 for treatment…
Responses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to start clinical study in the Third Quarter of 2018 WALTHAM, Mass., May 22, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with…
WALTHAM, Mass., June 09, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 6,666,667 shares of common stock (or common stock equivalents) and…
WALTHAM, MA, August 10, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the…